Phase II Trial of XL184 Cabozantinib an Oral Small-Molecule Inhibitor of Multiple
Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
A Window of Opportunity Study to Characterize the Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics of CPX-POM in Patients with Newly Diagnosed or Recurrent Bladder Tumors
A Phase III, Randomized, Double-blind Study of Encorafenib and Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Previously Untreated BRAF V600E/K Mutation-Positive Participants with Unresectable or Metastatic Melanoma. STARBOARD
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib NSC 748727 in Newly Diagnosed or Previously Untreated Low-Grade Glioma LGG Not Associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 NF1
A Phase III, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement
A PHASE 2/3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NKTR-255 VS PLACEBO FOLLOWING CD19-DIRECTED CAR-T CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA